DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH NEUROMUSCULAR DISEASES IN A REHABILITATION CLINIC OF A TERTIARY HEALTH CENTER: 5-YEAR RESULTS

Öz

Objectives: We aimed to investigate the demographic and clinical characteristics of patients who received inpatient physical therapy and rehabilitation programs for neuromuscular diseases (NMD) in a tertiary health center. Materials and Methods: This retrospective study examined patients who received a physical therapy program in the NMD clinic. Sociodemographic data, body mass index, muscle strength, sensory examination, presence of atrophy, presence of involuntary movements, spasticity examination, presence of dysphagia and dysarthria, respiratory system examination findings and functional status were recorded. Patients were divided into 3 groups: motor neuron diseases (group 1), neuropathies (group 2), and myopathies (group 3), and comparisons were made between the groups. Results: The highest number of patients was in the neuropathy group, followed by motor neuron disease (MND) and myopathy groups (n=146, 37, 21, respectively). The mean age was significantly lower in the myopathy group compared to the MND and neuropathy groups (p<0.001). History of fracture (p<0.001) and frequency of osteoporosis (p=0.016) were significantly higher in the MND group than in the neuropathy and myopathy groups. Upper extremity proximal muscle weakness was significantly higher in the myopathy group than in other groups (p=0.041). Sensory deficits were significantly higher in the neuropathy group compared to the MND and myopathy groups (p<0.001). Independent ambulation ratio was statistically significantly lower in the MND group than in the other two groups (p<0.01). Conclusion: MNDs are noted for fracture risk, difficulty in ambulation, and the need to use a device, while myopathies are marked by muscle weakness and neuropathies by sensory deficits.

Anahtar Kelimeler

• neuromuscular diseases
• Inpatients
• Rehabilitation

ÜÇÜNCÜ BASAMAK BİR SAĞLIK MERKEZİNİN REHABİLİTASYON KLİNİĞİNDE NÖROMUSKÜLER HASTALIKLAR NEDENİYLE TAKİP EDİLEN HASTALARIN DEMOGRAFİK VE KLİNİK ÖZELLİKLERİ: 5 YILLIK SONUÇLAR

Öz

Amaç: Üçüncü basamak bir sağlık merkezinde nöromusküler hastalıklar (NMH) nedeniyle yatarak fizik tedavi ve rehabilitasyon programı alan hastaların demografik ve klinik özelliklerini incelemeyi amaçladık. Materyal-Method: Çalışmamız NMH Kliniğinde yatarak fizik tedavi programı almış hastaların incelendiği retrospektif bir çalışmadır . Hastaların sosyodemografik verileri, vücut kitle indeksi, kas gücü, duyu muayenesi, atrofi varlığı, alt ekstremite eşitsizliği, spastisite muayenesi, disfaji ve dizartri varlığı, solunum sistemi muayenesi ve fonksiyonel durumları kaydedildi. Hastalar motor nöron hastalıkları (grup 1), nöropatiler (grup 2) ve miyopatiler (grup 3) grubu olmak üzere 3 gruba ayrılarak incelendi ve karşılaştırma yapıldı Bulgular: Çalışmamıza dahil edilen 204 hastaların dağılımına bakıldığında en fazla hasta sayısı nöropati grubundaydı, motor nöron hastalığı (MND) ve miyopati grubu sırasıyla takip etmekteydi (sırasıyla n= 146, 37, 21). Miyopati grubunda yaş ortalaması MND ve nöropati grubuna göre istatistiksel anlamlı düşüktü(p<0.001). MND grubunda geçmişte gelişen kırık öyküsü (p<0.001) ve osteoporoz sıklığı (p=0.016) , nöropati ve miyopati grubuna göre istatistiksel anlamlı yüksekti. Üst ekstremite proksimal kas güçsüzlüğü miyopati grubunda diğer gruplara göre istatistiksel anlamlı yüksekti (p=0.041). Nöropati grubunda MND ve miyopati grubuna göre duyusal kayıplar istatistiksel anlamlı yüksekti (p<0.001). Bağımsız ambulasyon MND grubunda diğer iki gruba göre istatistiksel anlamlı düşüktü (p<0.01). Sonuç: NMD alt gruplarını karşılaştırdığmız bu çalışmada MND kırık riski, ambulasyon zorluğu ve cihaz kullanımı gerekmesi ile öne çıkarken miyopatiler kas güçsüzlüğü ve nöropatiler de duyusal kayıplarla öne çıkmaktadır.

Anahtar Kelimeler

• nöromusküler hastalıklar
• yatan hastalar
• rehabilitasyon

Kaynakça

1. 1. Morrison BM. Neuromuscular diseases. Semin Neurol, 2016; 36: 409-18.
2. 2. Bertorini TE. Introduction: Evaluation of patients with neuromuscular disorders, in Neuromuscular Disorders: Treatment and Management. 2011, Elsevier. 3-19.
3. 3. NHÇ, G. Nöromuskuler Hastalıklar Tanı ve Tedavi Rehberi. Türk Nöroloji Derneği. 2007; 2:1-53.
4. 4. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Nöromüskül Dis. 2015; 2(1):73-85.
5. 5. Hartley SE, Goodwin PC, Goldbart J. Experiences of attendance at a neuromuscular centre: perceptions of adults with neuromuscular disorders. Disabil Rehabil. 2011; 33(12):1022-32.
6. 6. Bekiroğlu S, Çifci EG. Nöromüsküler Hasta Ailelerinin Yaşadıkları Güçlükler. Türkiye Sosyal Araştırmalar Dergisi. 2017; 21(3):704-22.
7. 7. Uçan H. Nöromüsküler Hastalıklar ve Tıbbi Rehabilitasyonu. Türkiye Klinikleri Physical Medicine Rehabilitation-Special Topics 2024; 17(2):1-12.
8. 8. Kent RD, Kent JF, Weismer G, Duffy JR. What dysarthrias can tell us about the neural control of speech. J Phon. 2000;28(3):273-302.

9. 9. Cup EH, Pieterse AJ, ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, et al. Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil. 2007; 88(11):1452-64.
10. 10. Voet NB. Exercise in neuromuscular disorders: a promising intervention. Acta Myol. 2019; 38(4):207-8
11. 11. Kılınç M, Yıldırım SA, Tan E. The effects of electrical stimulation and exercise therapy in patients with limb girdle muscular dystrophy: A controlled clinical trial. Neuron J. 2015; 20(3):259-66.
12. 12. Siciliano G, Schirinzi E, Simoncini C, Ricci G. Exercise therapy in muscle diseases: open issues and future perspectives. Acta Myol. 2019; 38(4):233-44.
13. 13. Carey IM, Nirmalananthan N, Harris T, DeWilde S, Chaudhry UA, Limb E, et al. Prevalence of co-morbidity and history of recent infection in patients with neuromuscular disease: A crosssectional analysis of United Kingdom primary care data. PLoS One. 2023;18(3):e0282513.
14. 14. Deenen JC, van Doorn PA, Faber CG, van der Kooi AJ, Kuks JB, Notermans NC, et al. The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands. Neuromuscul Disord. 2016;26(7):447-52.
15. 15. Mirian A, Aljohani Z, Grushka D, Florendo-Cumbermack A, Diagnosis and management of patients with polyneuropathy. CMAJ 2023; 195(6):E227-E33.
16. 16. Williams LM, Mcdonald CM. Myopathic Disorders in Braddom's Physical Medicine and Rehabilitation. 2021, Elsevier. 875-915. e3.
17. 17. Barzegar M, Niknam E, Habibi P, Shiva S, Tahmasebi S, Bone mineral density and bone metabolism in patients with Duchenne muscular dystrophy. Iran J Child Neurol. 2018; 12(1):77.
18. 18. Wasserman HM, Hornung LN, Stenger PJ, Rutter MM, Wong BL, Rybalsky I, et al. Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity. Neuromuscul Disord. 2017; 27(4):331- 7.
19. 19. Karaahmet ÖZ, Gürçay E, Yildizkan YT, Cankurtaran D, Bahtiyarca ZT, Umay E. Evaluation of bone health in terms of osteoporosis in adult patients with neuromuscular disease. Turk J Med Sci. 2024; 54(1):324-29.
20. 20. Pieterse A, Luttikhold T, De Laat K, Bloem B, Van Engelen B, Munneke M. Falls in patients with neuromuscular disorders. J Neurol Sci. 2006; 251(1-2):87-90.
21. 21. Perrin C, Unterborn JN, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve. 2004;29(1):5-27.
22. 22. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-49.
23. 23. Yamada H, Nishikawa T, Yamasaki M, Fukuba H, Ohmori H, Nakamura M, et al. Deep vein thrombosis in patients with neuromuscular disease who undergo tracheotomy with positive pressure ventilation. Neurol Clin Neurosci. 2021; 9(1):63-7.
24. 24. Gil J, Funalot B, Verschueren A, Danel‐Brunaud V, Camu W, Vandenberghe N, et al. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008; 15(11):1245-51.
25. 25. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E, Increased incidence of deep venous thrombosis in ALS. Neurol. 2007; 68(1):76- 7.
26. 26. Oczkowski WJ, Ginsberg JS, Shin A, Panju A. Venous thromboembolism in patients undergoing rehabilitation for stroke. Arch Phys Med Rehabil. 1992;73(8):712-6.
27. 27. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica 1997; 82(4):496-502.
28. 28. Gladman M, DeHaan M, Pinto H, Geerts W, Zinman L, Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study. Neurol. 2014; 82(19):1674-77.
29. 29. Finsterer J, Stöllberger C, Cardiac involvement in primary myopathies. Cardiol. 2000; 94(1):1-11.
30. 30. Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, et al. American Heart Association Pediatric Heart Failure Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Stroke Council. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017;136(13):e200-e31.
31. 31. Kim BJ, Nam JH, Kim HT, Park JI, Son JW, Echocardiographic Features in Neuromuscular Diseases. Circulation 2020; 142(Suppl_3):A15356-A56.
32. 32. Spurney CF, Cardiac complications of neuromuscular disorders. Neuromuscular Disorders: Management and Treatment E-Book: Expert Consult-Online and Print 2010; 33:125-32
33. 33. Yuksel ME, Tarakçıoğlu MC, Kılıçoğlu AG, Işık Ü, Bahçeci B, Elbay RY, et al. 9th International Congress on Psychopharmacology & 5th International Symposium on Child and Adolescent Psychopharmacology. Psychiatry Clin Psychopharmacol. 2017;27(sup1):216-319.
34. 34. Gylfadottir S, Dallimore M, Dean E, The relation between walking capacity and clinical correlates in survivors of chronic spinal poliomyelitis. Arch Phys Med Rehabil. 2006; 87(7):944-52.
35. 35. Mahar R, Kirby R, MacLeod D, Simulated leg-length discrepancy: its effect on mean center-of-pressure position and postural sway. Arch Phys Med Rehabil. 1985; 66(12):822-4.
36. 36. Verschueren A, Grapperon AM, Delmont E, Attarian S, Prevalence of spasticity and spasticity-related pain among patients with amyotrophic lateral sclerosis. Rev Neurol. 2021; 177(6):694-8.
37. 37. Knuijt S, Kalf JG, de Swart BJ, Drost G, Hendricks HT, Geurts AC, et al. Dysarthria and dysphagia are highly prevalent among various types of neuromuscular diseases. Disabil Rehabil. 2014; 36(15):1285- 89.
38. 38. Johnson LB, Florence JM, Abresch RT, Physical therapy evaluation and management in neuromuscular diseases. Phys Med Rehabil Clin. 2012; 23(3):633-51.
39. 39. García TP, Loureiro JP, González BG, Nieto-Rivero L, Assistive technology based on client-centered for occupational performance in neuromuscular conditions. Med. 2019; 98(25):e15983.
40. 40. Bahtiyarca ZT, Karaahmet ÖZ, Cankurtaran D, Umay E, Tombak Y, Ateş MP, Clinical profiles of neuromuscular disorders: a tertiary hospital experience. J Exp Clin Med. 2023; 40(3):522-9.